Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045 Meeting Abstract
| Authors: | Bellmunt, J.; de Wit, R.; Vaughn, D. J.; Fradet, Y.; Lee, J. L.; Fong, L.; Vogelzang, N. J.; Climent, M. A.; Petrylak, D.; Choueiri, T. K.; Necchi, A.; Gerritsen, W. R.; Gurney, H.; Quinn, D. I.; Culine, S.; Sternberg, C. N.; Jensen, E.; Frenkl, T.; Perini, R. F.; Bajorin, D. |
| Abstract Title: | Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigator's choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045 |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy283.110 |
| Language: | English |
| ACCESSION: | WOS:000459277302084 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy283.110 |
| Notes: | Meeting Abstract: 901P -- Appears on pages viii320-viii321 of the abstract book -- Source: Wos |
